Peptable

Comparison

CJC-1295 vs Retatrutide

Function

While CJC-1295 is used in research to chronically elevate endogenous growth hormone and IGF-1 levels, enabling studies of body composition, metabolic, and anti-aging effects of prolonged GH exposure10, Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575.

Mechanism

While CJC-1295 works as a tetrasubstituted 29-amino-acid analog of GHRH(1–29) that acts as a potent agonist at the GHRH receptor and, in its DAC form, covalently binds serum albumin to extend half-life from minutes to days, resulting in sustained pulsatile GH and IGF-1 increase1082, Retatrutide is a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575.

Receptor

CJC-1295

Growth hormone–releasing hormone receptor (GHRHR) on anterior pituitary somatotrophs1094103

Retatrutide

GLP-1 receptor (GLP1R), GIP receptor (GIPR), and glucagon receptor (GCGR) 256575

Organism or Origin

CJC-1295

Synthetic peptide based on human hypothalamic GHRH10120

Retatrutide

Synthetic multi-agonist peptide inspired by human incretins and glucagon657580

Gene

CJC-1295

GHRH

Retatrutide

Not assigned in the current dataset.

Summary

Both peptides fall into a similar broad context as Hormone peptides, although the details of how they are used and discussed still diverge. Both are often discussed in Metabolic and endocrine contexts, while CJC-1295 is more of a hormone peptide and Retatrutide is better described as a metabolic peptide. Both appear to work through Receptor agonist and Hormone analog, but the functional emphasis still separates, with CJC-1295 leaning toward Anabolic growth and Retatrutide leaning toward Metabolic regulation and Lipolysis and fat loss. Both are synthetic in origin with CJC-1295 in Preclinical development and Retatrutide in Clinical phase 3. CJC-1295 carries d-amino acid substitution features, while Retatrutide instead reflects lipidation changes.

Sources

10CJC-1295: Long-Acting GHRH Analog - Alpha Carbon Labs, https://alphacarbonlabs.com/blog/cjc-1295-long-acting-ghrh-analog
82CJC-1295 no DAC 5mg (Mod GRF 1-29), https://www.peptidesciences.com/mod-grf-1-29-5mg-cjc-1295-no-dac
94Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth-hormone-releasing_hormone_receptor
103Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone_releasing_hormone_receptor
120Growth hormone–releasing hormone - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone%E2%80%93releasing_hormone
25What is the mechanism of action of Retatrutide? - Patsnap Synapse, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-retatrutide
65Retatrutide Molecular Structure and Properties | Peptide Protocol Wiki, https://www.peptideprotocolwiki.com/peptides/retatrutide/molecule
75Retatrutide: The Triple Hormone Agonist (GLP-1/GIP/Gluc, https://formblends.com/research/glp-1/retatrutide-triple-agonist-guide
80GLP-1 Localisation and Proglucagon Gene Expression in ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6200298/